Toboroz
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193· 2. fázis· Vividion Therapeutics, Inc.· Forrás
Toboroz
A Study of Propranolol to Treat Kaposi Sarcoma
NCT05797662· 2. fázis· AIDS Malignancy Consortium· Forrás
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· 2/3. fázis· Exelixis· Forrás
Toboroz
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· 3. fázis· Nuvalent Inc.· Forrás
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852· 1. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Metabolic Effect of Exercise and Diet in Endometrial Cancer Patients Eligible for Staging Surgery.
NCT07025213· National Institute of Cancerología· Forrás
Toboroz
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma
NCT06560697· National Institute of Cancerología· Forrás
Toboroz
Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis
NCT06206083· National Institute of Cancerología· Forrás
Fut, nem toboroz
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer
NCT06477302· Instituto Nacional de Cancerologia de Mexico· Forrás
Toboroz
Curcumin Supplementation in Cervical Cancer
NCT06080841· National Institute of Cancerología· Forrás
Toboroz
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
NCT06238882· Instituto Nacional de Cancerologia de Mexico· Forrás
Fut, nem toboroz
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Pathogenic Variants in Genes Associated With Lung Adenocarcinoma
NCT06181812· Oscar Gerardo Arrieta Rodríguez· Forrás
Toboroz
Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer
NCT06883409· Instituto Nacional de Cancerologia de Mexico· Forrás
Toboroz
Alectinib Pharmacokinetic in Patients With NSCLC
NCT05713006· 1/2. fázis· Instituto Nacional de Cancerologia de Mexico· Forrás
Fut, nem toboroz
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239· 1. fázis· Boehringer Ingelheim· Forrás
Toboroz
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
NCT05445791· 3. fázis· Instituto Nacional de Cancerologia de Mexico· Forrás
Fut, nem toboroz
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT04575935· 3. fázis· M.D. Anderson Cancer Center· Forrás
Fut, nem toboroz
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Meghívásos bevonás
Effect of Two Cognitive-Behavioral Interventions on Cervical Cancer Patients
NCT04165460· National Institute of Cancerología· Forrás
Toboroz
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NCT04294927· University Medical Center Nijmegen· Forrás
Fut, nem toboroz
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500· 1/2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Oscillating Positive Expiratory Pressure Therapy for Patients With Thoracic Neoplasms Undergoing Chest Surgery
NCT05267496· Instituto Nacional de Cancerologia de Mexico· Forrás
Fut, nem toboroz
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
NCT04181970· Grupo Espanol de Investigacion en Sarcomas· Forrás
Fut, nem toboroz
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637· 3. fázis· OBI Pharma, Inc· Forrás
Toboroz
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients
NCT03803787· 2. fázis· Instituto Nacional de Cancerologia de Mexico· Forrás
Fut, nem toboroz
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608· 3. fázis· Pfizer· Forrás
Toboroz
Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients
NCT02978521· Instituto Nacional de Cancerologia de Mexico· Forrás
Toboroz
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
NCT02734069· Instituto Nacional de Cancerologia de Mexico· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703· 3. fázis· Eli Lilly and Company· Forrás